Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - AccuredReceivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Janux Therapeutics (JANX) Common Equity: 2020-2025

Historic Common Equity for Janux Therapeutics (JANX) over the last 5 years, with Sep 2025 value amounting to $976.6 million.

  • Janux Therapeutics' Common Equity rose 48.84% to $976.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $976.6 million, marking a year-over-year increase of 48.84%. This contributed to the annual value of $1.0 billion for FY2024, which is 197.02% up from last year.
  • Latest data reveals that Janux Therapeutics reported Common Equity of $976.6 million as of Q3 2025, which was down 1.41% from $990.5 million recorded in Q2 2025.
  • Janux Therapeutics' Common Equity's 5-year high stood at $1.0 billion during Q4 2024, with a 5-year trough of $299.5 million in Q2 2023.
  • Moreover, its 3-year median value for Common Equity was $656.1 million (2024), whereas its average is $661.4 million.
  • As far as peak fluctuations go, Janux Therapeutics' Common Equity skyrocketed by 2,602.58% in 2021, and later decreased by 12.90% in 2023.
  • Janux Therapeutics' Common Equity (Quarterly) stood at $366.3 million in 2021, then dropped by 12.44% to $320.7 million in 2022, then climbed by 7.36% to $344.3 million in 2023, then soared by 197.02% to $1.0 billion in 2024, then soared by 48.84% to $976.6 million in 2025.
  • Its last three reported values are $976.6 million in Q3 2025, $990.5 million for Q2 2025, and $1.0 billion during Q1 2025.